Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of GS-9450 in Chronic Hepatitis C Virus Infection
2008-007456-96Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nivocasan in chronic hepatitis C (CHC) and hepatitis C virus infection (3 arms), sponsored by Gilead Sciences. Primary endpoint: Histologic response at Week 24. Started May 2009; status: completed.
02
Drugs
nivocasan
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on 2008-007456-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007456-96.